CStone targets European expansion with EMA filing for Sugemalimab in stage III NSCLC
CStone Pharmaceuticals seeks EMA approval for sugemalimab in stage III NSCLC, aiming to expand lung cancer immunotherapy options in Europe. Read More
CStone advances CS5001 clinical trial for first-line DLBCL treatment in Australia
CStone Pharmaceuticals has taken a significant step in the development of its ROR1 antibody-drug conjugate with the submission of a Phase Ib clinical trial application ... Read More
CStone Pharmaceuticals advances CS2009 clinical trial, targeting multi-billion-dollar immunotherapy market
CStone Pharmaceuticals has officially commenced the Phase I clinical trial for CS2009, a cutting-edge PD-1/VEGF/CTLA-4 trispecific antibody, marking a significant step in the company’s commitment ... Read More
CStone Pharmaceuticals partners with SteinCares to expand cancer treatment in Latin America
CStone Pharmaceuticals, a leading biopharmaceutical company specializing in innovative cancer therapies, has entered a landmark partnership with SteinCares, a Latin American pharmaceutical leader. This collaboration ... Read More
CStone Pharmaceuticals advances cancer research with first-in-human clinical trial application for CS2009
CStone Pharmaceuticals, an innovation-driven biopharmaceutical company listed on the Hong Kong Stock Exchange (HKEX: 2616), has taken a significant step forward in its mission to ... Read More
CStone Pharmaceuticals receives positive CHMP opinion for Sugemalimab in NSCLC treatment
CStone Pharmaceuticals (HKEX: 2616), a leading innovation-driven biopharmaceutical company from China, announced a significant milestone with the Committee for Medicinal Products for Human Use (CHMP) ... Read More
CStone’s sugemalimab gains CHMP recommendation for NSCLC treatment
CStone Pharmaceuticals has reached a pivotal milestone in its global strategy, with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ... Read More
CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer
US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological ... Read More